Abstract

Cross-Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment

Adv Sci (Weinh). 2024 Nov;11(41):e2308313. doi: 10.1002/advs.202308313.Epub 2024 Sep 7.

Junhui Li 1 2Tarini Shankar Ghosh 1 2Elke Arendt 1 3Fergus Shanahan 1 4Paul W O'Toole 1 2

 
     

Author information

1APC Microbiome Ireland, University College Cork, Cork, T12 K8AF, Ireland.

2School of Microbiology, University College Cork, Cork, T12 K8AF, Ireland.

3School of Food and Nutritional Sciences, University College Cork, Cork, T12 K8AF, Ireland.

4Department of Medicine, University College Cork, Cork, T12 K8AF, Ireland.

Abstract

Irritable bowel syndrome (IBS) is a prevalent disorder of gut-brain interaction without a reliable cure. Evidence suggests that an alteration of the gut microbiome may contribute to IBS pathogenesis, motivating the development of microbiome-targeted therapies to alleviate IBS symptoms. However, IBS-specific microbiome signatures are variable across cohorts. A total of 9204 datasets were meta-analyzed, derived from fourteen IBS microbiome discovery cohorts, three validation cohorts for diet-microbiome interactions, and five rifaximin therapy cohorts. The consistent bacterial species and functional signatures associated with IBS were identified. Network analysis revealed two distinct IBS-enriched microbiota clusters; obligate anaerobes that are found commonly in the gut, and facultative anaerobes typically present in the mouth, implying a possible association between oral bacterial translocation to gut and IBS pathogenesis. By analyzing diet-microbiome interactions, microbiota-targeted diets that can potentially modulate the altered gut microbiota of IBS subjects toward a healthy status were identified. Furthermore, rifaximin treatment of IBS subjects was linked with a reduction in the abundance of facultatively anaerobic pathobionts. Gut microbiome signatures were identified across IBS cohorts that may inform the development of therapies for microbiome modulation in IBS. The microbiota-targeted diet patterns described may enable nutritional intervention trials in IBS and for assisting dietary management.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.